About Vesugen
Tripeptide bioregulator targeting vascular endothelium; normalizes gene expression in smooth muscle and endothelial cells; reduces lipid accumulation in vessel walls
Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed gene expression regulatory mechanisms acting on endothelial and smooth muscle cell populations. Like other Khavinson bioregulator peptides, vesugen is proposed to modulate gene expression in target vascular cells through interactions with chromatin regulatory elements and transcription factor binding sites, with effects proposed to support endothelial integrity and vascular wall homeostasis under conditions of aging-related cellular stress. Published research on Khavinson-class short peptides has characterized systematic gene expression regulatory effects and cell differentiation regulatory capacity across multiple tissue types, providing the class-level mechanistic framework within which vesugen's vascular effects are proposed. Vesugen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.
Vesugen Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Russian vascular peptide bioregulator (Lys-Glu-Asp) from Khavinson Institute. Developed for vascular endothelium health. Not FDA-approved. Not on any FDA list. Research chemical.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 moderate
2 Reviews
Peptide Regulation of Gene Expression: A Systematic Review
Molecules · 2021
This systematic review documents the gene expression regulatory properties of short peptides including vesugen (Lys-Glu-Asp from vascular tissue), showing chromatin-binding activity and selective gene modulation in endothelial and vascular smooth muscle cells relevant to vascular aging and endothelial health.
Short Peptides in the Treatment of Age-Related Diseases
Stem Cell Reviews and Reports · 2020
This review summarizes the geroprotective properties of short regulatory peptides including vesugen, documenting effects on vascular tissue function, endothelial health, and longevity outcomes in animal models, with clinical data from the Khavinson program showing reduced vascular age-related pathology in treated cohorts.
Vesugen Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Vesugen — Providers & Availability
2 providersClinics
1 providerStay updated on verified Vesugen providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Vesugen
Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed gene expression regulatory mechanisms acting on endothelial and smooth muscle cell populations. Like other Khavinson bioregulator peptides, vesugen is proposed to modulate gene expression in target vascular cells through interactions with chromatin regulatory elements and transcription factor binding sites, with effects proposed to support endothelial integrity and vascular wall homeostasis under conditions of aging-related cellular stress.
vascular repair, endothelial function, cardiovascular anti-aging, atherosclerosis reduction.
Research on Vesugen primarily documents effects related to vascular repair and endothelial function and cardiovascular anti-aging and atherosclerosis reduction. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Vesugen include none established. This is educational information only — consult a qualified healthcare professional before use.
2 providers in the directory currently offer Vesugen.
This systematic review documents the gene expression regulatory properties of short peptides including vesugen (Lys-Glu-Asp from vascular tissue), showing chromatin-binding activity and selective gene modulation in endothelial and vascular smooth muscle cells relevant to vascular aging and endothelial health.